CARDIACUS cancer geneticae temptationis
Post decem fere annos evolutionis, tumor geneticus probatus statim necessarius factus est magno numero aegrorum cancri. Expertus relatio ductu proviso per tumorem geneticum experimentum evolutionis notionis praecisionis medicinae perfecte convenit, et in omnes aspectus diagnosis et curationis tumoris aegros penetravit. Aegris, medicamenta iaculis ad curationem accuratam eligere possunt, ambages vitare, et effectus supervacuos vitare. amarus.
Current status de targeted Lorem CARDIACUS cancer
In most cases, surgery is still the main treatment for gastric cancer. However, the heterogeneity of gastric cancer is very strong, and its biological behavior is affected by the huge gene regulation in the cell. Therefore, only by classifying the essential characteristics of gastric cancer from the molecular level can early diagnosis and prognosis judgment of the tuberculum be more reasonable and accurate , Application of molecular targeted drugs for individualized and precise treatment of patients.
Hoc tempore, sequenti medicinae targeted quia probatus est:
| Serial numerus | Target | pharmacum |
| 1 | HER2 | Trastuzumab (trastuzumab, Herceptin) |
| 2 | VEGFR | Ramucirumab |
| 3 | NTRK | Larotrectinib (Loxo-CI) |
| 4 | PD-1 | Pembrolizumab (pharmacum K) |
| 5 | II-VEGFR | Apatinib (Apatinib, aitan) |
Praeter multa alia medicamenta iaculis medicamentis gastrici in clinicis iudiciis pertinentia sunt, ut medicamenta quae claudunt HER2: lapatinib (Tykerb ®), pertuzumab (Perjeta ®) et trastuzumab emtansine (Kadcyla ®). Medicamenta quae scandalum EGFR: Panitumumab (Victibi®) est medicamentum quod scuta EGFR tentatur pro cancro gastrico.
Global Oncologist Network omnes admonet probatio genetica ante iaculis justo requiritur. Tantum intelligendo genus tumoris gene mutationis potest rationabilis curationis consilium promoveri ut aegros prodesset. Praeterea in delectu technologiae geneticae probationis, oportet eligere opportunam probationem technologiam secundum suum scopum respondentem. Tantum fructus eligendo probatos Civitatis Food et Drug Administration potest accuratio et fides testium eventus praestari.
CARDIACUS cancer cum aegris quomodo geneticae temptationis eligere?
The Global Oncologist Network aegros admonet ut cancer geneticae probationis et curationi clinicae analyseos sint systematicum consilium quod validum laboratorium subsidium requirit, summus vexillum probatio qualitatis imperium et summus gradus analyseos turmae. Bonus analysis geneticae experimentalis occasiones curationis amissionem vitare potest et animas aegros cancer serpit. Nunc, justos geneticae probationis institutiones in foro sunt, et aegros diligenter eligere debent societates geneticae probationis ut subtilitatem testium proventuum curent.
Hic est a geneticae temptationis probatus per FDA technology!
FoundationOne®CDx
FoundationOne®CDx fuit approbata per FDA sicut primum genus particeps Diagnostic productum Pan-tumore . As a research tool, it assisted the discovery of countless scientific research results, and accumulated a large amount of data during this period. The current test coverage includes 324 genes and two molecular markers (MSI / TMB) that can predict the efficacy of immune checkpoint inhibitors. It can cover all solid tumors (except sARCOMA) and can directly correspond to 17 probatus per FDA targeted therapies!
Pro clinico aestimatione genesis cancer, vulgo technicae artis adhibitae, includunt Sanger sequencing, spectrometriam massam genotyping, fluorescentiam in situ hybridizationis (PISIS) et analysi immunohistochemicae (IHC). "Latin detectio singularis titulus" ut Piscium, IHC et multi-gena hotspot detectio (panel hotspot) non potest nisi unam vel duas species abnormitates geneticae notabilis amet (quales tantum substitutiones turpes). Studia demonstraverunt novissimam comprehensive generationis sequentis technologiam pro cancro probatio geneticae comprehensivae omnes quattuor species abnormitatum geneticae (basis subrogationis; insertio et deletio; exemplum numeri variationis et rearrangement), et accuratius quam traditum, vexillum probat.
Quomodo cancer aegris FoundationOne® CDX subituri tentationis?
In Sinis, hoc est provisum est a servitio analysis Dean Diagnostics. Global oncologist possum Network adiuvaret cancer aegris est accipere servitium, vel geneticae exploranda summa auctoritate domestica elit. Global oncologist Network, ut bene nota domesticis cancer patientes estote servitium suggestus, fuit et Oncology centro et bene notum cancer peritis operari proxime simul ut regulariter organize harum magnarum medicus, patientes estote commutationem conventus popularis scientia lectionibus auxilium aegris adepto ut de mensuris et tantae auctoritatis in consiliis diagnosis et curatio peritorum consul domi & foris, remedii rate amplio. Nos tibi semper et facere conatus ad introducendam anti-cancer notitia ducens mundi, technology, peritis medicinae, orci iudiciis, etc., et ut quoquo modo melius anti-cancer cum aegris magis providere servicia.
CancerFax ut bene notum domesticis cancer diagnosis et curatio consulting et servitium amet, sunt credita sunt providente primum-genus anti-cancer servicia pro domesticis cancer aegris, inter quas tardus anti-cancer technology et summo cancer peritus opibus, profecta est maxima tumore collatis consiliis in India consilia centrum, et ad cooperandum celebre consilium centers tumor, necnon virorum peritorum in Civitatibus Foederatis Americae, Sina, Israel, et facti in Europa est optimum tumore diagnosis et curatio consulting robore ad faciendum opus mundi.
